Press releases
- Heron Therapeutics Announces Acceptance of the Prior Approval Supplement Application for ZYNRELEF® Vial Access Needle ("VAN")
- Heron Therapeutics Announces Prior Approval Supplement Submission to the FDA for ZYNRELEF® Vial Access Needle ("VAN")
- Heron Therapeutics Announces First Quarter 2024 Financial Results and Highlights Recent Corporate Updates
- Heron Therapeutics to Report First Quarter 2024 Financial Results on Tuesday, May 7, 2024
- Heron Therapeutics to Host Investor Day on May 15, 2024 in New York City
More ▼
Key statistics
On Wednesday, Heron Therapeutics Inc (AXD2:DUS) closed at 2.51, -29.45% below its 52-week high of 3.56, set on Jun 04, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 2.60 |
---|---|
High | 2.60 |
Low | 2.51 |
Bid | -- |
Offer | -- |
Previous close | 2.51 |
Average volume | 0.00 |
---|---|
Shares outstanding | 150.65m |
Free float | 149.60m |
P/E (TTM) | -- |
Market cap | 412.79m USD |
EPS (TTM) | -0.6156 USD |
Data delayed at least 15 minutes, as of Jul 03 2024 18:31 BST.
More ▼